Compare Quest Diagnostics Inc (DGX) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B). The key difference: Quest Diagnostics Inc is far larger — about 4.3× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and State Street SPDR Bloomberg High Yield Bond ETF for 61 Days on average.
| DGX | JNK | |
|---|---|---|
Market Cap | $25.48B | $5.86B |
Volume | 941,866 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $98.02 |
52-Week Low | $173.49 | $92.30 |
Typical Hold Time | 56 Days | 61 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
JNK trades at $92.73, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments of $0.53 per share through 2026. Recent institutional activity shows Envestnet Asset Management increased its stake by 23.3% during the latest quarter, indicating institutional confidence despite broader market volatility in high-yield bonds.
The outlook remains cautious amid rising Treasury yields and geopolitical tensions affecting bond markets. Key risks include interest rate sensitivity and economic slowdown concerns. Current technical support sits at $92 with resistance at $93, suggesting limited near-term price movement absent significant market catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
